New medicine launches: 72.9% of US physicians and other prescribers would try one in its first months when it is covered, 22.9% when patients pay $250 a month
Coverage, more than trial data, decides it in practice: 72.9% of US prescribers outside dermatology are likely to prescribe a newly launched medicine with a clear phase 3 benefit in its first months when it is covered without prior authorization, 54.3% when prior authorization is needed and 22.9% when a patient pays $250 a month, even though 55.7% name trial data as their single biggest trigger (n=70, November 2026).
- Who was asked
- HCP Other (Non-Derm), 70 clones, US
- When
- November 2026 (fielded 12 November 2026)
- How
- Predicted responses from Brox clones, each built from a long-form interview with a real person.
- What changed from the obvious question
- The obvious question asks doctors to rank what influences them. We asked that once, as a single forced pick, and then gave the same 70 prescribers three versions of one launch, identical except for insurance access: covered with a $30 copay, covered after a one to two week prior authorization, and not covered at $250 a month. Comparing each clone's own answers across the three shows what coverage does, not only what prescribers say about it.
Section 01: What the panel said
- #
22.9%
22.9% (16 of 70) are likely, a 6 or 7 of 7, to prescribe a new medicine with a clear phase 3 benefit in the next three months when most plans do not cover it and a patient pays about $250 a month, against 72.9% (51 of 70) when it is covered with no prior authorization and a $30 copay, and 54.3% (38 of 70) when prior authorization takes one to two weeks.
base 70
- #
55.7%
55.7% (39 of 70) name phase 3 trial results as the single factor that would most make them prescribe a new medicine in its first six months, 30.0% (21) coverage without prior authorization, 10.0% (7) a respected colleague and 4.3% (3) a rep visit; of the 21 who name coverage, 17 are likely to prescribe the covered medicine and 1 the uncovered one.
base 70 · contrast
- #
15.7%
15.7% (11 of 70) are very likely, a 7 of 7, to prescribe once prior authorization is needed, against 42.9% (30 of 70) without it; prior authorization mostly costs enthusiasm, as 80.0% (56 of 70) still rate the medicine 5 or higher.
base 70 · contrast
- #
8
8 of the 12 clones whose interviews describe an oncology practice stay likely to prescribe the uncovered medicine, against 8 of the other 58; specialty was not asked, so this split is read from the interviews and is a direction only.
base 12 · Clones describing an oncology practice · caveat
22.9% (16 of 70) are likely, a 6 or 7 of 7, to prescribe a new medicine with a clear phase 3 benefit in the next three months when most plans do not cover it and a patient pays about $250 a month, against 72.9% (51 of 70) when it is covered with no prior authorization and a $30 copay, and 54.3% (38 of 70) when prior authorization takes one to two weeks.
02Where does a newly launched medicine lose prescribers?
At the point a patient has to pay for it. The same 70 prescribers read three versions of one launch, identical except for insurance access. With coverage and no prior authorization, 51 of the 70 are likely to prescribe it in the next three months. A one to two week prior authorization takes that to 38, and no coverage with a $250 monthly bill takes it to 16. Almost nobody moves the other way: 68 of the 70 clones never rate a harder version of the launch higher than an easier one.
Prior authorization mainly costs enthusiasm. The top rating, a 7 of 7, falls from 30 clones to 11 once prior authorization is needed, but 56 of the 70 still rate the medicine 5 or higher. Losing coverage is different: 36 of the 70 (51.4%) rate it 3 or lower, and 19 of the 51 who were likely to prescribe it when it was covered fall that far.
03Do the prescribers who put trial data first hold out when coverage fails?
Partly. Of the 39 who name phase 3 results as their single biggest trigger, 29 are likely to prescribe the covered medicine and 14 still are when a patient pays $250 a month. Of the 21 who name coverage, 17 are likely to prescribe the covered medicine and only 1 is once it is not covered. Their stated priority predicts how hard the cliff hits them.
Oncology is the exception. Specialty was not asked, but 12 of the clones describe an oncology practice in their interviews, and 8 of those 12 stay likely to prescribe the uncovered medicine, against 8 of the other 58. Outside oncology, likely intent falls from 41 of 58 with coverage to 8 of 58 without it.
04What gets a prescriber past prior authorization?
No single fix stands out. Asked what would most make them prescribe a new medicine that needs prior authorization anyway, 30.0% (21 of 70) pick free medicine while the approval is pending, 28.6% (20) a manufacturer program that completes the paperwork, 24.3% (17) their own staff already having had approvals for it, and 17.1% (12) none of these.
The free medicine lead comes from oncology, where 8 of the 12 pick it. Among the other 58, the paperwork program leads with 18, then staff experience with 17, free medicine with 13 and none with 10. None of the 12 who would stay with the current treatment rate the prior authorization scenario above a 5.
05What would a launch or market access team do with this?
- Our reading, not the panel's answer: a strong trial result earns interest, and coverage turns it into prescriptions. Likely intent is 72.9% (n=70) with coverage and 22.9% without it, for the same trial result.
- Our reading: a launch that starts behind prior authorization keeps most of its willing prescribers but loses its enthusiasts, as 7 of 7 ratings fall from 30 to 11 of 70.
- Our reading: access support is specialty-specific. Oncology prescribers lean toward free medicine during the wait, others toward help with the paperwork or their own staff's experience.
06What do people also ask?
- What share of doctors would prescribe a new medicine that insurance does not cover yet? 22.9% (n=70) of US prescribers outside dermatology are likely to prescribe it in its first months when a patient would pay about $250 a month, against 72.9% when it is covered.
- How much does prior authorization cut early prescribing of a new medicine? Likely intent falls from 72.9% to 54.3% (n=70) with a one to two week prior authorization, and the share very likely to prescribe falls from 42.9% to 15.7%.
- What share of physicians say trial data is the main reason they try a new medicine? 55.7% (n=70) name phase 3 results showing a clear benefit as the single biggest trigger, against 30.0% for coverage without prior authorization, 10.0% for a colleague and 4.3% for a rep visit.
Section 07: What they said, and the interview line it rests on
“I would say I'm pretty unlikely to prescribe it right away—probably a 2. Even if a clinical trial shows clear benefit over the standard treatment, cost and access drive so much of my day-to-day decision-making. In primary care, I have to be realistic about what patients can actually get and maintain. If an effective standard treatment already exists and insurance doesn't cover the new one, asking someone to shell out $250 a month out of pocket is just a huge hurdle. I tend to prescribe what I know will be covered and approved so my patients don't run into roadblocks at the pharmacy. Now, because I work with mostly commercially insured, white-collar patients, if someone specifically knows about it, understands the cost, and really wants to try it, I'm a team-approach provider and I'm open to discussing it. But as a routine clinical choice in the first three months before insurance formulary adoption kicks in? I'm almost always going to stick with the accessible standard of care.”
Predicted from this line in the interview
“A lot of times, people are like, well, why'd you choose that medicine? And because that's what your insurance covered, or I know something will be too expensive. It's not because I don't think it's right for you, it's just because you won't have access to it otherwise.”
“For me, it really comes down to the clinical evidence, specifically Phase 3 trial results showing a clear benefit over the current standard of care. When a new drug launches or I'm considering prescribing something I haven't used before, my first step is always to look at the published literature—typically the randomized controlled trial—to evaluate the trial data and labeled indications. I was trained relatively recently in an academic center, so sticking closely to evidence-based guidelines and clinical trial data is core to how I practice. While insurance hurdles and prior authorizations are definitely frustrations in healthcare, my clinic staff handles almost all the paperwork and prior auths, sheltering me from that administrative burden, and while I might hear about a drug initially from a talk or a rep, I wouldn't prescribe it without verifying the trial data myself.”
Predicted from this line in the interview
“Well, I would… I would start with the article, like, the… usually it's a randomized control trial, so I'll look at that. I'll see, like, the labeled indication or whatever.”
“In neuro-oncology, when we have a promising new treatment, we want to get patients started on it right away—we don't have time to wait around for insurance bureaucracy while a tumor is progressing. My clinic already has an incredible support team with clinic nurses and nurse practitioners who handle our prior authorization paperwork and logistics, so an outside service doing the paperwork isn't what moves the needle for me. What makes the biggest difference is having bridge supply or free medicine for the patient while that prior authorization is pending. It ensures there is zero delay in their care, and it takes away the stress and financial burden for patients who are already dealing with a devastating diagnosis.”
Predicted from this line in the interview
“Where my patients cannot afford healthcare, they are skipping prescriptions, they are in serious financial turmoil with their cancer diagnosis.”
Section 08: How much should you trust this?
What we would defend
- The access ladder within the same 70 clones: likely intent falls from 72.9% to 54.3% to 22.9% as the same launch moves from covered, to prior authorization, to uncovered at $250 a month; 68 of the 70 never rate a harder version higher, and every answer to the uncovered version reasons from the $250 cost.
- That prior authorization costs enthusiasm more than willingness: 7 of 7 ratings fall from 42.9% to 15.7% (n=70) while 80.0% still rate the medicine 5 or higher.
- Trial data as the most named single trigger, 55.7% (n=70), with rep visits last at 4.3%.
What we would not
- Any of these as a measured national uptake rate: these are 70 clones answering written scenarios, and every scenario answer was inferred from the clones' interviews rather than stated in them, as answers to a hypothetical launch must be.
- The trigger ranking as a measured share of real prescribers: 67 of the 70 answers to that question were inferred rather than stated in the interviews, so it reads as direction.
- The oncology split (8 of 12 against 8 of 58): specialty was not asked and was read from interview text.
- A ranking of prior authorization supports: free medicine, a paperwork program and staff experience sit at 21, 20 and 17 of 70, and the free medicine lead comes from oncology.
- A price threshold: only $250 a month was tested, so the point where intent collapses could sit lower.
- Any split by age, gender or region: those demographics are missing for all 70 clones.
The main limitation
These are 70 clones of US prescribers outside dermatology answering three written versions of one unnamed launch; stated intent in a scenario is not a measured uptake rate, and the panel is small enough that only the whole-panel figures are given as percentages.
Section 09: How was this run?
| Segment | Clones |
|---|---|
| Describe an oncology practice in their interviews | 12 |
| Other specialties, including primary care, cardiology, gastroenterology and pediatrics | 58 |
Question wording as fielded
- Are you currently authorized to prescribe prescription medicines in the United States? (added by Ask Brox as a screener; 70 of 70 qualified)
- When a new prescription medicine launches in your area of practice, which one of these would most make you prescribe it to a suitable patient within its first six months on the market?
- Imagine a new prescription medicine launched three months ago in your area of practice. Its phase 3 trial showed a clear benefit over the current standard treatment, and most of your patients' insurance plans cover it with no prior authorization, at a typical patient copay of $30 a month. On a scale of 1 to 7, where 1 is very unlikely and 7 is very likely, how likely are you to prescribe it to a suitable patient in the next three months?
- Imagine a new prescription medicine launched three months ago in your area of practice. Its phase 3 trial showed a clear benefit over the current standard treatment, but most of your patients' insurance plans require prior authorization for it, which typically takes your office one to two weeks, and the patient copay once approved is $30 a month. On a scale of 1 to 7, where 1 is very unlikely and 7 is very likely, how likely are you to prescribe it to a suitable patient in the next three months?
- Imagine a new prescription medicine launched three months ago in your area of practice. Its phase 3 trial showed a clear benefit over the current standard treatment, but most of your patients' insurance plans do not cover it yet, so a patient would pay about $250 a month out of pocket. On a scale of 1 to 7, where 1 is very unlikely and 7 is very likely, how likely are you to prescribe it to a suitable patient in the next three months?
- When a newly launched prescription medicine requires prior authorization from most of your patients' insurance plans, which one of these would most make you prescribe it anyway?
What was not asked, and why
No medicine, company, disease or specialty was named, and specialty itself was not asked. The uncovered version offered no copay card or patient assistance, only one out-of-pocket price ($250 a month) was tested, and step therapy, samples and formulary tiers were not. Ask Brox added one check that each clone is authorized to prescribe in the US, which all 70 passed.
What changed from the obvious question
The obvious question asks doctors to rank what influences them. We asked that once, as a single forced pick, and then gave the same 70 prescribers three versions of one launch, identical except for insurance access: covered with a $30 copay, covered after a one to two week prior authorization, and not covered at $250 a month. Comparing each clone's own answers across the three shows what coverage does, not only what prescribers say about it.
Fielded through Ask Brox on 12 November 2026.
More on How doctors decide what to prescribe · Pharma & HCP · HCP Other (Non-Derm) (US) panel
Ask this of your own customers: humans@brox.ai
Related insights
All in this topic-
Medical science liaisons: 60.1% of US physicians and other prescribers want real-world and subgroup evidence for patients like theirs, and 65.2% rate a liaison meeting useful against 17.7% for a sales rep
65.2% 65.2% rate a 20-minute meeting with a medical science liaison at least moderately useful to their practice, against 17.7% for a 20-minute meeting with a sales representative about the same kind of medicine (base 198)
Read -
Patient out-of-pocket cost and prescribing: US physicians keep a preferred brand at $25 a month, split at $75, and 62.9% switch to a generic at $150
37.1% 37.1% (26 of 70) would still prescribe the brand-name medicine they prefer when it costs the patient $150 a month against $5 for an older generic, down from 95.7% (67 of 70) at $25 and 55.7% (39 of 70) at $75; none of the 70 moves back to the brand as the price rises. (base 70)
Read -
Pharma rep visits: 66.7% of US clinicians, mostly dermatologists, would turn away a rep who asks to come every two weeks, against 39.4% for a monthly visit
66.7% Asked by a rep for a medicine they already prescribe for a 10-minute in-person visit, 66.2% of US clinicians would agree to one every three months, 58.1% to one a month and 31.8% to one every two weeks; the share who would decline rises from 30.8% to 39.4% to 66.7%. (base 198)
Read -
Oral JAK inhibitor or biologic: 88.9% of US dermatologists start a pill-seeking eczema patient on the JAK, and only a $150 a month gap tips most to the biologic
88.9% For a healthy 35-year-old with moderate-to-severe eczema who dislikes injections and asks for a pill, 88.9% of US dermatologists would start an oral JAK inhibitor rather than an injectable biologic when both cost the patient $0 a month; 81.7% still would when the JAK costs $30 a month more, 69.0% at $75 more and 46.8% at $150 more. (base 126)
Read